NYU: GLP-1 Receptor Agonists and Hair Loss: What a Mendelian Randomization Study Reveals About Genetic Risk

03 Sep NYU: GLP-1 Receptor Agonists and Hair Loss: What a Mendelian Randomization Study Reveals About Genetic Risk

Dr. Petukhova

MedicalResearch.com: What is the background for this study? What are the main findings?

Dr. Petukhova: As GLP-1 receptor agonists such as Ozempic and Wegovy are increasingly used for type 2 diabetes and weight loss, questions have emerged about whether these medications may be linked to hair loss. Some cases may reflect telogen effluvium, a temporary shedding that can occur after rapid weight loss or major metabolic stress. However, recent observational studies have suggested there may also be a link with androgenetic alopecia, or patterned hair loss, in some individuals. According to the National Institute of Diabetes and Digestive and Kidney Diseases, GLP-1 receptor agonists are among the most prescribed medication classes for type 2 diabetes and obesity management, making the safety and side effect profile of these drugs a growing area of clinical research.

Watch the interview in Video format

To examine this question, we used a genetic epidemiology approach called two-sample Mendelian randomization. In simple terms, this method uses naturally occurring genetic variation to test whether a biological pathway is likely to play a causal role in disease. We studied genetic variants associated with higher GLP1R expression — the gene encoding the receptor targeted by drugs such as Ozempic — and tested whether those variants were associated with male pattern hair loss. We found that genetically increased GLP1R expression was associated with a modest but statistically significant increase in the risk of male pattern hair loss. The association was robust, as it remained directionally consistent across multiple sensitivity analyses and after adjustment for possible mediating factors including weight, blood pressure, insulin, and testosterone.

MedicalResearch.com: Is the hair loss experienced by some individuals on GLP-1 users related primarily to temporary telogen effluvium?

Dr. Petukhova: Telogen effluvium is likely part of the explanation, especially in the setting of rapid weight loss. Major changes in body weight, calorie intake, and nutritional status can trigger temporary hair shedding, and in many people that hair does regrow over time. Our study suggests, however, that temporary shedding may not be the whole story. The findings raise the possibility that in some individuals, particularly those with a genetic predisposition to patterned hair loss, GLP-1–related hair changes may be more than just transient telogen effluvium.

MedicalResearch.com: Is the gene associated with androgenic hair loss in men with a possible increased risk of GLP-1 alopecia also found in women, or is this gene Y-linked?

Dr. Petukhova: The gene that we studied, GLP1R, is not a sex-linked or Y-linked gene; it is present and active in both men and women. The reason our analysis focused on men is not because the gene is male-specific, but because large-scale genetic datasets currently exist for male pattern hair loss and are lacking for female pattern hair loss. We also identified some smaller published gene-expression data that we analyzed. Our results suggest that there is higher GLP1R expression in men with male pattern hair loss compared to men without it, but comparable studies in women are still limited. So at this point, the question in women remains open because the data are not yet available at the same scale. This is something that our group is actively trying to change.

MedicalResearch.com: What recommendations do you have for future research as a result of this study?

Dr. Petukhova: The next step would ideally be replication in an independent cohort, but that is challenging because there is currently only one large genetic dataset for male pattern hair loss, and there is no comparable large-scale genetic study of female pattern hair loss. Our group is interested in helping address that gap, although building these cohorts takes substantial time and resources. In the nearer term, an important priority is mechanistic work. For example, larger transcriptomic studies of scalp tissue in both male and female patterned hair loss could help clarify whether GLP1R signaling is biologically involved. Prospective clinical studies would also be valuable to determine whether people with a high genetic risk of patterned hair loss are more likely to develop clinically meaningful hair loss after starting GLP-1 receptor agonists.

MedicalResearch.com: Is there anything else you would like to add?

Dr. Petukhova: Hair loss is sometimes dismissed as a cosmetic issue, but it can have a substantial effect on quality of life and emotional well-being, so it deserves careful study. Our findings do not establish that GLP-1 receptor agonists directly cause patterned hair loss in all users, but they do suggest that genetic susceptibility may play a role in at least some cases. If future studies confirm this, it could eventually help identify patients at higher risk and guide counseling or preventive strategies.

Disclosures: Dr. Petukhova previously served as a paid consultant for Veradermics, unrelated to this study.

For a broader overview of what the research shows about GLP-1 receptor agonists including semaglutide and their effects beyond blood glucose and weight, see this MedicalResearch.com overview of GLP-1 receptor agonists and what the research shows beyond weight loss.

Citation:

Disclaimer: The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Some links are sponsored. MedicalResearch.com and Eminent Domains Inc. do not warrant or endorse products or claims made by third party links. Always seek the advice of your physician or other qualified health provider and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

Last Updated on September 3, 2026 by Marie Benz MD FAAD